Underpinning Voyager’s mission is its trademark AAV capsid-discovery platform, Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER). This broadly applicable, functional ...

With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid engineering techniques are taking on this challenge. Clinical translation of gene therapies has a history ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

Adeno-associated viral (AAV) vectors have emerged as the leading gene delivery platform for gene therapy. Capsid proteins play an important role in cell binding, internalization, and trafficking, ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit. The Vericheck ddPCR Empty-Full Capsid ...

Sangamo Therapeutics Inc.’s second large, worldwide licensing deal for its capsid technology in the past five months is with Astellas Pharma Inc. The California-based company is getting $20 million up ...

Sandy Macrae, Chief Executive Officer, Sangamo "We strongly believe in the potential of STAC-BBB, our industry-leading, intravenously delivered AAV capsid, to overcome the challenges associated ...